SFI
ELVN icon

Susquehanna Fundamental Investments’s Enliven Therapeutics ELVN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,334
Closed -$568K – 623
2025
Q2 		$568K Hold
28,334
– – 0.02% 532
2025
Q1 		$558K Buy
+28,334
New +$610K 0.01% 818
2021
Q1 		– Sell
-2,337
Closed -$206K – 1555
2020
Q4 		$206K Sell
2,337
-813
-26% -$68.2K ﹤0.01% 1351
2020
Q3 		$256K Buy
3,150
+1,250
+66% +$113K 0.01% 1115
2020
Q2 		$210K Buy
+1,900
New +$213K 0.01% 833

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Susquehanna Fundamental Investments's ELVN Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Enliven Therapeutics (ELVN) in Q3 2025, closing a stake of 28,334 shares — an estimated $568K sold.

Susquehanna Fundamental Investments first reported a position in ELVN in Q2 2020 and held it in 5 quarters. The position peaked at $568K in Q2 2025. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • Susquehanna Fundamental Investments reported no remaining Enliven Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 28,334 Enliven Therapeutics shares in Q3 2025, an estimated $568K.
  • Susquehanna Fundamental Investments first reported a position in Enliven Therapeutics in Q2 2020 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Enliven Therapeutics position peaked at $568K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.